Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist (2013) 1.64

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood (2011) 1.61

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma (2012) 1.47

Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica (2011) 1.32

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood (2011) 1.32

IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica (2013) 1.26

Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia (2013) 1.20

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06

Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04

Multiple myeloma. Curr Probl Cancer (2009) 1.04

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica (2012) 1.03

Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol (2012) 1.02

European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist (2012) 0.98

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. Rev Bras Hematol Hemoter (2013) 0.98

Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol (2010) 0.96

Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96

Therapeutic advancements in multiple myeloma. Front Oncol (2014) 0.96

Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant (2014) 0.91

Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res (2010) 0.89

Living with multiple myeloma: experiences of patients and their informal caregivers. Support Care Cancer (2009) 0.88

Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia (2013) 0.88

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica (2010) 0.88

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica (2010) 0.85

Diagnosis and therapy of multiple myeloma. Korean J Intern Med (2013) 0.84

Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. J Geriatr Oncol (2016) 0.84

Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst (2014) 0.83

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81

Current therapeutic strategies for multiple myeloma. Int J Clin Oncol (2015) 0.81

How best to use new therapies in multiple myeloma. Blood Rev (2010) 0.81

Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81

Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. Patient Prefer Adherence (2014) 0.80

Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. J Adv Pract Oncol (2013) 0.80

New Treatment Approaches for Older Adults with Multiple Myeloma. J Geriatr Oncol (2012) 0.79

Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics (2009) 0.78

Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol (2013) 0.78

Tretatment approach of nontransplant patients with multiple myeloma. Mater Sociomed (2014) 0.78

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. Chin Med J (Engl) (2016) 0.78

Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant (2009) 0.78

The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis (2010) 0.78

Thrombosis in multiple myeloma (MM). Hematology (2012) 0.78

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77

Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer (2013) 0.77

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Med (2016) 0.75

Is the low-thalidomide dose MPT regimen beneficial? Korean J Intern Med (2011) 0.75

Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy. Stem Cells Int (2015) 0.75

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma. J Res Med Sci (2012) 0.75

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. Biomed Res Int (2016) 0.75

Evolving role of high dose stem cell therapy in multiple myeloma. Indian J Med Paediatr Oncol (2011) 0.75

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. J Korean Med Sci (2013) 0.75

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean J Intern Med (2016) 0.75

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group. Hematol Rep (2012) 0.75

Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res (2011) 0.75

Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. Onco Targets Ther (2016) 0.75

Crossover confusion: MPT still best. Blood (2008) 0.75

Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leuk Suppl (2013) 0.75

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. Eur J Clin Pharmacol (2015) 0.75

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30

International staging system for multiple myeloma. J Clin Oncol (2005) 11.29

BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05

Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet (2010) 5.59

Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet (2006) 5.07

A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood (2006) 3.17

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84

Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood (2011) 2.74

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood (2012) 2.68

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58

Maternal complications and procedures in pregnancy and at birth and wheezing phenotypes in children. Am J Respir Crit Care Med (2006) 2.56

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol (2004) 2.36

Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 2.18

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood (2004) 2.17

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood (2010) 2.09

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood (2003) 2.00

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98

A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest (2005) 1.93

p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res (2006) 1.92

Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma (2008) 1.85

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J (2003) 1.81

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79

Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood (2011) 1.76